Compare VC & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VC | MIRM |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2000 | 2019 |
| Metric | VC | MIRM |
|---|---|---|
| Price | $100.34 | $65.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $129.08 | $87.55 |
| AVG Volume (30 Days) | 308.0K | ★ 578.2K |
| Earning Date | 10-23-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.17 | N/A |
| Revenue | ★ $3,759,000,000.00 | $471,794,000.00 |
| Revenue This Year | N/A | $53.78 |
| Revenue Next Year | $3.92 | $19.91 |
| P/E Ratio | $8.95 | ★ N/A |
| Revenue Growth | N/A | ★ 53.66 |
| 52 Week Low | $65.10 | $36.88 |
| 52 Week High | $129.10 | $78.55 |
| Indicator | VC | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 40.36 | 35.77 |
| Support Level | $98.57 | $63.48 |
| Resistance Level | $103.38 | $71.98 |
| Average True Range (ATR) | 2.74 | 3.12 |
| MACD | 0.21 | -0.49 |
| Stochastic Oscillator | 44.38 | 18.08 |
Visteon Corp is an automotive supplier. It manufactures electronics products for original equipment vehicle manufacturers including Ford, Nissan, Renault, Mazda, BMW, General Motors, and Honda, etc. The company offers information displays, instrument clusters, head-up displays, infotainment systems, telematics solutions, and Smartcore. The Company's reportable segment is Electronics. The Electronics segment provides vehicle cockpit electronics products to customers, including digital instrument clusters, domain controllers with integrated driver assistance systems, displays, Android-based infotainment systems, and battery management systems. Geographically, it operates in North America, Europe, China, Asia-Pacific, and South America and Others.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.